Last reviewed · How we verify
Boesenbergia
Boesenbergia is a Small molecule drug developed by Mahidol University. It is currently in Phase 3 development.
Boesenbergia is a genus of plants in the ginger family, native to China, the Indian subcontinent, and Southeast Asia, containing over 90 species. Boesenbergia is being studied as a potential treatment in clinical trials for conditions such as COVID-19, radiation-induced mucositis, and head and neck cancer, alongside other interventions like Andrographis Paniculata.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Boesenbergia |
|---|---|
| Sponsor | Mahidol University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Andrographis Paniculata vs Boesenbergia Rotunda vs Control in Asymptomatic COVID-19 (PHASE3)
- Prevention of Mucositis in Patients With Head and Neck Cancer Treated With Radiotherapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Boesenbergia CI brief — competitive landscape report
- Boesenbergia updates RSS · CI watch RSS
- Mahidol University portfolio CI
Frequently asked questions about Boesenbergia
What is Boesenbergia?
Who makes Boesenbergia?
What development phase is Boesenbergia in?
Related
- Manufacturer: Mahidol University — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing